Research Evidence
Every paper we cite, and how to judge one yourself.
Our product pages cite 23 peer-reviewed papers across 6 compounds. This page lists all of them in one place and explains how to work out what any single paper does and does not establish.
We have not written a summary of what this research shows, and that is deliberate. A vendor's summary of its own products' literature is the least trustworthy document in the chain, and you have no way to check it without reading the papers anyway.
So the citations below link straight to PubMed, and the section underneath explains how to read one. If our reading of a paper and yours disagree, yours is the one that counts.
Reading a paper
Four questions, in order.
Ask these of any citation, on this site or anyone else's. The first one does most of the work.
01
What was actually studied?
Cells in a dish, an animal model, or people. This single fact changes what a result means more than anything else in the paper, and it is usually in the first line of the abstract's methods.
Where to look: On a PubMed record, read the Methods sentence in the abstract. Words like in vitro, cell line, murine, rat, or healthy volunteers tell you immediately.
02
Is it a primary study or a review?
A primary study reports original measurements. A review discusses other people's studies. Both are useful and they are not interchangeable, and a review citing a weak study does not make it stronger.
Where to look: PubMed labels this for you. Look at the Publication Types field on the record — it will say Review, Randomized Controlled Trial, Meta-Analysis, and so on.
03
How many, and for how long?
A result in eight animals over two weeks and a result in four hundred people over a year are not the same kind of evidence, even when the headline sounds identical.
Where to look: Sample size and duration are almost always in the abstract. If a paper does not state them plainly, that is itself worth noticing.
04
Who funded it, and does the journal say?
Funding does not invalidate a study, but it belongs in your reading of it. Good papers disclose it.
Where to look: Check the Conflict of Interest or Funding statement on the full record. Its absence is as informative as its contents.
Transfer
What a result does not carry with it.
Evidence does not move cleanly from one setting to the next. Something measured in a cell culture may not occur in a living animal, because a cell in a dish has no liver, no immune system and no circulation. Something measured in a mouse may not occur in a person, because dose, metabolism and lifespan all differ.
This is not a reason to dismiss early work. It is a reason to keep the setting attached to the claim. A finding in rats is a finding in rats, and it stays that way until somebody runs the study in people.
Much of the literature on research peptides is preclinical. That is an honest description of where the field is, not a criticism of it.
Citations
The papers behind our product pages.
Grouped by compound, exactly as they appear on each product page. Every entry links to its PubMed record so you can read the abstract, the publication type and the funding statement yourself.
Retatrutide
4 papers- 1.Coskun T, Urva S, Roell WC, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. PubMed 35985340
- 2.Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. PubMed 37366315
- 3.Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. PubMed 37385280
- 4.Urva S, O'Farrell L, Du Y, et al. (2023). The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes Obes Metab. PubMed 37311727
MOTS-c
3 papers- 1.Lee C, Zeng J, Drew BG, et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. PubMed 25738459
- 2.Kim KH, Son JM, Benayoun BA, et al. (2018). The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab. PubMed 29983246
- 3.Reynolds JC, Lai RW, Woodhead JST, et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. PubMed 33473109
TB-500
4 papers- 1.Safer D, Elzinga M, Nachmias VT (1991). Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. PubMed 1999398
- 2.Malinda KM, Sidhu GS, Mani H, et al. (1999). Thymosin beta4 accelerates wound healing. J Invest Dermatol. PubMed 10469335
- 3.Bock-Marquette I, Saxena A, White MD, et al. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. PubMed 15565145
- 4.Goldstein AL, Hannappel E, Sosne G, et al. (2012). Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. PubMed 22074294
GHK-Cu
4 papers- 1.Maquart FX, Pickart L, Laurent M, et al. (1988). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. PubMed 3169264
- 2.Pickart L, Vasquez-Soltero JM, Margolina A (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. PubMed 26236730
- 3.Pickart L, Margolina A (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. PubMed 29986520
- 4.Pickart L, Vasquez-Soltero JM, Margolina A (2012). The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxid Med Cell Longev. PubMed 22666519
BPC-157
4 papers- 1.Sikiric P, Seiwerth S, Rucman R, et al. (2011). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. PubMed 21548867
- 2.Chang CH, Tsai WC, Lin MS, et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). PubMed 21030672
- 3.Hsieh MJ, Liu HT, Wang CN, et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). PubMed 27847966
- 4.Vasireddi N, Hahamyan H, Salata MJ, et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. PubMed 40756949
Tesamorelin
4 papers- 1.Ferdinandi ES, Brazeau P, High K, et al. (2007). Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. PubMed 17214611
- 2.Falutz J, Allas S, Blot K, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. PubMed 18057338
- 3.Baker LD, Barsness SM, Borson S, et al. (2012). Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. PubMed 22869065
- 4.Stanley TL, Feldpausch MN, Oh J, et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. PubMed 25038357
Limits
What a citation is not.
Not a claim that it works
Citing a paper says the research exists and we have read where it was published. It does not say the result will hold anywhere else, or that we are asserting it.
Not a safety assessment
None of this literature was selected for safety data, and a study reporting an effect is not a study establishing that a compound is safe.
Not an endorsement by the authors
The researchers cited here have no connection to this company and have not reviewed, approved or commented on our catalog.
Not a complete literature review
These are the papers behind what our product pages state. They are not every paper on each compound, and we have not weighted them against contradicting work.
All products are intended strictly for laboratory research use only. Not for human consumption. Not for medical, diagnostic, therapeutic, veterinary, or household use. Product information is provided for research identification and catalog purposes only.